Indianapolis, IN based Eli Lilly and Company (LLY - Free Report) , is a global healthcare company with core products in a number of primary-care pharmaceutical markets. Lilly generates revenues from its pharmaceutical product and animal health segments.
The company’s portfolio includes Zyprexa (schizophrenia and bipolar disorder), Gemzar (pancreatic cancer), Evista (osteoporosis), Cymbalta (depression), Cialis (erectile dysfunction), Strattera (attention deficit hyperactivity disorder - ADHD), Erbitux (cancer) and Alimta (chemotherapy). Lilly also has a strong presence in the diabetes market. However, many of its key products like Cymbalta and Alimta are facing generic competition. The company also has some new products like Trulicity, Cyramza and Taltz in its portfolio which have started contributing to revenues.
LLY’s earnings track record has been pretty good with the company delivering positive earnings in three of the last four quarters with an average surprise of 4.31%.
Currently, LLY has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Miss: LLY missed on third quarter earnings. The company reported EPS of 88 cents while our consensus called for EPS of 96 cents.
Revenues Miss: Revenues also missed expectations. Lilly posted revenues of $5.19 billion, compared to our consensus estimate of $5.35 billion.
Revised 2016 Outlook: The company revised the revenue guidance to a range of $ $20.8 billion - $21.2 billion from $20.6 billion - $21.1 billion. Lilly continues to expect earnings per share in the range of $3.50 - $3.60. The Zacks Consensus Estimate for earnings and revenues is $3.59 per share and $21.20 billion.
Stock Price Impact: Shares declined almost 3% in pre-market trading.
Check back later for our full write up on this LLY earnings report later!
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Indianapolis, IN based Eli Lilly and Company (LLY - Free Report) , is a global healthcare company with core products in a number of primary-care pharmaceutical markets. Lilly generates revenues from its pharmaceutical product and animal health segments.
The company’s portfolio includes Zyprexa (schizophrenia and bipolar disorder), Gemzar (pancreatic cancer), Evista (osteoporosis), Cymbalta (depression), Cialis (erectile dysfunction), Strattera (attention deficit hyperactivity disorder - ADHD), Erbitux (cancer) and Alimta (chemotherapy). Lilly also has a strong presence in the diabetes market. However, many of its key products like Cymbalta and Alimta are facing generic competition. The company also has some new products like Trulicity, Cyramza and Taltz in its portfolio which have started contributing to revenues.
LLY’s earnings track record has been pretty good with the company delivering positive earnings in three of the last four quarters with an average surprise of 4.31%.
Currently, LLY has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Miss: LLY missed on third quarter earnings. The company reported EPS of 88 cents while our consensus called for EPS of 96 cents.
Revenues Miss: Revenues also missed expectations. Lilly posted revenues of $5.19 billion, compared to our consensus estimate of $5.35 billion.
Revised 2016 Outlook: The company revised the revenue guidance to a range of $ $20.8 billion - $21.2 billion from $20.6 billion - $21.1 billion. Lilly continues to expect earnings per share in the range of $3.50 - $3.60. The Zacks Consensus Estimate for earnings and revenues is $3.59 per share and $21.20 billion.
Stock Price Impact: Shares declined almost 3% in pre-market trading.
Check back later for our full write up on this LLY earnings report later!
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on LLY - FREE